Cetuximab combined with chemotherapy prolonged the overall survival of advanced NSCLC
- VernacularTitle:西妥昔单抗联合化疗延长晚期非小细胞肺癌患者生存期
- Author:
Gang CHENG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Targeted therapy;
Antibodies,monoelonal
- From:
Cancer Research and Clinic
2008;20(8):505-506
- CountryChina
- Language:Chinese
-
Abstract:
The latest results from the FLEX trial wag presented in ASCO annual meeting which was hold in June.2008 in Chicago.The study demonstrated that chemotherapy based on Cetuximab plus Cisplatin significantly increased the overall survival of NSCLC patients,including all histological subtypes.The new findings confirm that Erbitux is the first targeted thempy to show a significant survival benefit in NSCLC patients across all histological subtypes.
